Inebilizumab

Inebilizumab (previously known as MEDI-551) is a humanized mAb that binds to and depletes CD19+ B cells including plasmablasts and plasma cells. Inebilizumab is currently being tested in a phase 2 study for treating Neuromyelitis Optica Spectrum Disorder (NMOSD). NMOSD is a rare autoimmune disorder in which immune system cells and autoantibodies attack and damage the optic nerves and spinal cord. Clinically, the disease is manifested with attacks/relapses that result in neurological impairment such as blindness, paraplegia, sensory loss, bladder dysfunction, and peripheral pain. The disability from each attack is cumulative, making NMOSD a chronically debilitating and potentially life-threatening disease.[1]

Inebilizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetCD19
Clinical data
Other namesMEDI-551
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6504H10080N1732O2044S44
Molar mass146652.90 g·mol−1

This drug was developed by Viela Bio and MedImmune, LLC.

References
  1. "Portfolio | Viela Bio". Viela Bio. Retrieved 2018-11-14.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.